Theravance Biopharma Inc (NASDAQ:TBPHV) was downgraded by analysts at Robert W. Baird from a “neutral” rating to an “underperform” rating in a report released on Wednesday. They presently have a $24.00 price objective on the stock, up from their prior price objective of $19.00. Robert W. Baird’s price target suggests a potential upside of 23.08% from the stock’s current price.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

5 Day Chart for NASDAQ:TBPHV

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with's FREE daily email newsletter.